资料单张
NERISONE
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
NERISONE
CREAM, OINTMENT,
FATTY OINTMENT
Corticoid skin preparations
COMPOSITION
1 g Nerisone contains
diflucortolone
valerate (6alpha,9-difluoro-11beta-hydroxy-21-valeryloxy-16alpha-methyl-1,4-
pregnadiene-3,20-dione) 1 mg. The cream contains methylparaben 0,07% and propylparaben 0,03%.
PHARMACOLOGICAL CLASSIFICATION
A. 13.4.1 Corticosteroids without anti-infective agents.
PHARMACOLOGICAL ACTION
Diflucortolone valerate is an effective corticoid. On topical application it suppresses inflammation in inflammatory and
allergic skin conditions and ameliorates the subjective complaints, such as itching, burning and pain. Diflucortolone
valerate is incorporated in three bases formulated to suit the respective skin condition.
INDICATIONS
All skin diseases which respond to topical corticoid therapy, eg contact dermatitis, contact eczema, occupational eczema;
vulgar, nummular (microbial), degenerative and seborrhoeic eczema; dyshidrotic eczema; eczema in varicose syndrome
(excluding ulcers); anal eczema; eczema in children; neurodermatitis (endogenous eczema, atopic dermatitis); psoriasis;
lichen ruber planus et verrucosus; lupus erythematosus; first degree burns, sunburn, insect bites.
CONTRA-INDICATIONS
Tuberculous and syphilitic processes in the area to be treated, virus diseases (herpes simplex, vaccinia, varicella and
smallpox).
Potent topical corticosteroid preparations (Nerisone) should not be applied to any skin crease areas.
Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed
percutaneously, teratogenicity following topical application cannot be excluded. Therefore Nerisone should not be used
during pregnancy.
DOSAGE AND DIRECTIONS FOR USE
Unless otherwise prescribed by the doctor, the Neri
阅读完整的文件
资料单张 